Analysts Set Roivant Sciences Ltd. (NASDAQ:ROIV) Target Price at $29.50

Shares of Roivant Sciences Ltd. (NASDAQ:ROIV) have been given a consensus rating of “Moderate Buy” by the eleven analysts that are covering the stock, MarketBeat Ratings reports. One research analyst has rated the stock with a sell rating, one has assigned a hold rating and nine have assigned a buy rating to the company. The average 12-month price target among analysts that have updated their coverage on the stock in the last year is $29.50.

Several brokerages have issued reports on ROIV. The Goldman Sachs Group raised their target price on Roivant Sciences from $24.00 to $33.00 and gave the stock a “buy” rating in a research report on Monday, December 15th. Sanford C. Bernstein assumed coverage on shares of Roivant Sciences in a research report on Friday. They set an “outperform” rating and a $35.00 price target for the company. Citigroup increased their price objective on shares of Roivant Sciences from $26.00 to $35.00 and gave the stock a “buy” rating in a research note on Tuesday, February 10th. HC Wainwright raised their price objective on shares of Roivant Sciences from $33.00 to $34.00 and gave the stock a “buy” rating in a report on Wednesday, March 4th. Finally, TD Cowen restated a “buy” rating on shares of Roivant Sciences in a research report on Wednesday, March 4th.

Roivant Sciences Price Performance

ROIV stock opened at $27.93 on Friday. Roivant Sciences has a 1 year low of $8.73 and a 1 year high of $30.33. The company has a market cap of $19.99 billion, a P/E ratio of -23.87 and a beta of 1.17. The stock’s fifty day moving average price is $26.03 and its 200-day moving average price is $21.42.

Insider Buying and Selling at Roivant Sciences

In other news, CEO Eric Venker sold 200,000 shares of the business’s stock in a transaction on Friday, February 13th. The shares were sold at an average price of $26.49, for a total transaction of $5,298,000.00. Following the completion of the sale, the chief executive officer owned 1,654,597 shares of the company’s stock, valued at $43,830,274.53. The trade was a 10.78% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available at this link. Also, Director Daniel Allen Gold sold 425,000 shares of the firm’s stock in a transaction on Wednesday, February 11th. The stock was sold at an average price of $26.67, for a total value of $11,334,750.00. Following the completion of the transaction, the director directly owned 15,928,113 shares in the company, valued at approximately $424,802,773.71. This represents a 2.60% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Over the last quarter, insiders have sold 6,187,954 shares of company stock worth $159,440,314. 10.80% of the stock is owned by insiders.

Institutional Inflows and Outflows

Several institutional investors have recently made changes to their positions in ROIV. Oregon Public Employees Retirement Fund lifted its position in shares of Roivant Sciences by 0.6% during the 4th quarter. Oregon Public Employees Retirement Fund now owns 87,152 shares of the company’s stock valued at $1,891,000 after buying an additional 500 shares in the last quarter. Bank of Montreal Can increased its holdings in Roivant Sciences by 1.3% in the 4th quarter. Bank of Montreal Can now owns 40,012 shares of the company’s stock worth $868,000 after acquiring an additional 516 shares in the last quarter. Bessemer Group Inc. raised its stake in Roivant Sciences by 41.5% during the 3rd quarter. Bessemer Group Inc. now owns 1,852 shares of the company’s stock worth $28,000 after acquiring an additional 543 shares during the period. Allworth Financial LP raised its stake in Roivant Sciences by 48.1% during the 3rd quarter. Allworth Financial LP now owns 1,795 shares of the company’s stock worth $27,000 after acquiring an additional 583 shares during the period. Finally, Fifth Third Bancorp lifted its holdings in Roivant Sciences by 15.8% during the fourth quarter. Fifth Third Bancorp now owns 4,310 shares of the company’s stock valued at $94,000 after purchasing an additional 588 shares in the last quarter. Institutional investors own 64.76% of the company’s stock.

Roivant Sciences Company Profile

Roivant Sciences is a biopharmaceutical company focused on the development and commercialization of innovative therapies through a network of subsidiary businesses known as “Vants.” Founded in 2014, Roivant acquires or in-licenses clinical-stage assets that have progressed beyond proof of concept and seeks to advance them efficiently toward regulatory approval. By organizing each program into a dedicated subsidiary, the company aims to streamline decision-making, allocate resources more effectively, and accelerate development timelines.

The core activities of Roivant involve identifying promising drug candidates across a range of therapeutic areas, including neurology, rare diseases, immunology, oncology, and women’s health.